The stock of Biocryst Pharmaceuticals Inc. (BCRX) has gone up by 2.59% for the week, with a -12.29% drop in the past month and a -27.81% drop in the past quarter. The volatility ratio for the week is 6.01%, and the volatility levels for the past 30 days are 6.60% for BCRX.. The simple moving average for the past 20 days is -7.25% for BCRX’s stock, with a -32.59% simple moving average for the past 200 days.

Is It Worth Investing in Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) Right Now?

compared to its average ratio and a 36-month beta value of 1.84. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”

Elon Musk just Triggered a BOOM in These Stocks

Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"

Click Here to Download the FREE Report.


The average price point forecasted by analysts for Biocryst Pharmaceuticals Inc. (BCRX) is $15.00, which is $9.86 above the current market price. The public float for BCRX is 200.81M, and currently, short sellers hold a 15.00% ratio of that float. The average trading volume of BCRX on November 17, 2023 was 2.87M shares.

BCRX) stock’s latest price update

The stock of Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) has decreased by -1.34 when compared to last closing price of 5.21.Despite this, the company has seen a gain of 2.59% in its stock price over the last five trading days. GlobeNewsWire reported 2023-10-27 that RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present two abstracts on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). The meeting will take place at the Anaheim Convention Center in Anaheim, Calif., from November 9-13, 2023.

Analysts’ Opinion of BCRX

Many brokerage firms have already submitted their reports for BCRX stocks, with RBC Capital Mkts repeating the rating for BCRX by listing it as a “Outperform.” The predicted price for BCRX in the upcoming period, according to RBC Capital Mkts is $10 based on the research report published on September 18, 2023 of the current year 2023.

BCRX Trading at -18.01% from the 50-Day Moving Average

After a stumble in the market that brought BCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.90% of loss for the given period.

Volatility was left at 6.60%, however, over the last 30 days, the volatility rate increased by 6.01%, as shares sank -10.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.96% lower at present.

During the last 5 trading sessions, BCRX rose by +2.59%, which changed the moving average for the period of 200-days by -51.14% in comparison to the 20-day moving average, which settled at $5.51. In addition, Biocryst Pharmaceuticals Inc. saw -55.23% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at BCRX starting from SANDERS MACHELLE, who sale 4,000 shares at the price of $7.98 back on Jun 15. After this action, SANDERS MACHELLE now owns 25,611 shares of Biocryst Pharmaceuticals Inc., valued at $31,920 using the latest closing price.

Hutson Nancy J, the Director of Biocryst Pharmaceuticals Inc., sale 12,866 shares at $8.04 during a trade that took place back on Jun 14, which means that Hutson Nancy J is holding 81,818 shares at $103,443 based on the most recent closing price.

Stock Fundamentals for BCRX

Current profitability levels for the company are sitting at:

The net margin for Biocryst Pharmaceuticals Inc. stands at -91.24. The total capital return value is set at -31.82, while invested capital returns managed to touch -53.21.

When we switch over and look at the enterprise to sales, we see a ratio of 4.35, with the company’s debt to enterprise value settled at 0.30. The receivables turnover for the company is 6.77 and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.90.


To put it simply, Biocryst Pharmaceuticals Inc. (BCRX) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.